Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Autism Spectrum DisorderAsperger SyndromeAspergers Syndrome
Interventions
DRUG

Milnacipran

Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.

DRUG

Placebo

Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.

Trial Locations (1)

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Montefiore Medical Center

OTHER